Printer Friendly

Articles from M2 Pharma (January 17, 2019)

1-24 out of 24 article(s)
Title Author Type Words
Abbott exercises option to purchase Cephea Valve Technologies. 160
Acurx Pharmaceuticals LLC awarded the US FDA's fast track designation for 362E for Clostridium difficile Infection. 258
Acurx Pharmaceuticals' C. difficile drug receives Fast Track designation from UD FDA. 188
Amgen & UCB wins the US FDA BRUDAC's recommendation for approval of EVENITY for treating osteoporosis in postmenopausal women. 316
Anokion Names Simon Cooper as Chief Medical Officer. 333
Aradigm Announces Detailed Third Party Evaluation Results for Apulmiq /Linhaliq. Financial report 1403
Bioharmony Therapeutics signs collaborative research and licensing agreement with Boehringer Ingelheim. 160
Biomunex Pharmaceuticals signs licensing agreement with Sanofi. 157
Bridge wins US FDA's orphan drug designation for BBT-877 in IPF, with first-in-human clinical study set to begin next month. Clinical report 286
Dance Biopharm Names Development, Finance Chiefs. 506
European Commission Approves Erleada for Non-Metastatic Castration-Resistant Prostate Cancer Patients Who Are at High Risk of Developing Metastatic Disease. 498
Exelixis' CABOMETYX tablets receive US FDA approval. 194
Immuno Concepts wins US FDA 510(k) clearance for the Histofluor Rodent Tissue Slides. 217
Knopp Biosciences Expands Research Collaboration with Cincinnati Children's to Characterise Effect of Dexpramipexole in Inflammatory Diseases. 328
MIM Software Inc awarded US FDA's 510(k) clearance for molecular radiotherapy dosimetry. 181
Onstryv Approved for Parkinson's Disease in Canada. 452
PharmaCyte Biotech Partner Encapsulates Live Cells for Clinical Trial in Pancreatic Cancer. 414
Protagonist Therapeutics awards stock options to new EVP of clinical operations and pharmacology Suneel Gupta, PhD. 164
Revance Eyes USD 100m from Common Stock Offering. 197
Sandoz Inc unveils SYMJEPI (epinephrine) in the US allergy market. 177
Targovax wins patent for Mutant-RAS neoantigen platform lead products in Europe. 202
The US FDA authorises the first generic Sabril for the treatment of complex partial seizures in adults and pediatric patients. 217
Therachon awarded US FDA's orphan drug designation for apraglutide for the treatment of short bowel syndrome. 190
US FDA Accepts Investigational New Drug Application to Evaluate Hyleukin-7, Atezolizumab in Patients with High-Risk Skin Cancers. 361

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters